Real-World Experience of Hepatitis C Treatment With Glecaprevir-Pibrentasvir During Pregnancy.
Oct 7, 2026DOI: 10.1093/cid/ciag422Journal ArticleCID
Written by: L Madeline McCraryMegan R CurtisJeannie C KellyJessica Elrod-GallegosPatrick KojimaPatricia WernerJennifer L MullersmanTracey Habrock-BachMichael J DurkinLaura R Marks
Find these authors on Roon
MM
Dr. Madeline McCrary
General ID · WUSTL
JK
Dr. Jeannie Kelly
MFM · WUSTL
Summary
Guidelines endorse antenatal hepatitis C virus treatment following shared decision making. No clinical trial or real-world data exist for glecaprevir-pibrentasvir (GLE/PIB). We report our experience with prenatal GLE/PIB in 14 patients. Ten patients completed treatment; all achieved virologic response by or at delivery, with no maternal or neonatal safety concerns.
JK
Dr. Jeannie Kelly
Obstetrics & Gynecology (OBGYN) · Maternal Fetal Medicine (MFM)Washington University in St. LouisdrjeanniekellySt. Louis, MO